Current status of research and development of neuropathic pain drugs

Author: Millet Bug

Neuropathic pain (NP) is pain caused by somatosensory system damage or disease.

The pathogenesis of neuropathic pain is complex, including peripheral sensitization, central sensitization, and central downward inhibitory regulation changes

There are many targets for neuropathic pain drugs.

1.

The role of Nav1 channel subtypes in neuropathic pain has been a research hotspot in recent years.

The excitatory transmitter glutamate is the key to initiating neuropathic pain.

2.

Acetylcholine is a chemical neurotransmitter of the central and peripheral cholinergic system

The monoaminergic system has a complex regulatory role in pain transmission.

Angiotensin 2 receptor (ATR2) is widely expressed in human nociceptive neurons, and its role in neuropathic pain has been confirmed in clinical trials.

The new opioid receptor target-orphaninfin receptor (OPRL1) has been emphasized because it reduces the dependence of opioids and the adverse reactions of other central drugs.

The adverse reactions and abuse of existing therapeutic drugs for neuropathic pain have not been improved.

Reference

[1] Song Jianan, Yu Haibo, Liu Yumei.

[2].